Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older at the time you give your consent to participate
- You are in generally good physical condition and able to carry out daily activities with little or no limitation (confirm with trial site)
- You have been formally diagnosed with multiple myeloma (MM) according to recognised medical guidelines
- You have already received at least 3 previous treatment regimens, which must have included three specific types of therapy: a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody (confirm with trial site for specific drugs that qualify)
- Your multiple myeloma has been shown to be getting worse or progressing, based on recognised medical guidelines
- Your disease can be measured through tests at the start of the study (screening)
- Your bone marrow, liver, kidneys, and blood counts are functioning well enough, as shown by tests at the start of the study
Who may not be able to join:
- You have had serious side effects from a previous CAR T-cell therapy or similar T-cell-based treatment
- You have a history of a non-blood cancer, unless you have been free of that cancer with no signs of it returning for at least 2 years (some exceptions may apply — confirm with trial site)
- You have significant heart, neurological, or psychiatric conditions
- You have a serious active or uncontrolled infection
- You have an active autoimmune disease, or have had one within the past 2 years
- You have active plasma cell leukaemia at the time of screening
- You have signs of dementia, confusion, or have had a stroke, brain bleed, or seizure within the 6 months before signing the consent form
- There is evidence that your multiple myeloma has spread to, or is affecting, your brain or spinal cord
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Phase 1b: Adverse Events (AEs); Phase 1b: Dose-Limiting Toxicities (DLTs); Phase 2: Objective Response Rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.